Mounjaro
- Active ingredient
- tirzepatide
- Class
- GIP and GLP-1 receptor agonist (dual agonist)
- Route
- Once-weekly subcutaneous injection
- Maker
- Eli Lilly
Educational only. This is educational, not medical advice. Everyone's body responds differently. Talk to your clinician before starting, stopping, changing, or tapering any medication, and work with your physician and a registered dietitian to personalize your approach.
Overview
Mounjaro is the type 2 diabetes brand of tirzepatide, a dual GIP/GLP-1 receptor agonist. It lowers blood sugar and, like its weight-management twin Zepbound, strongly reduces appetite.
People prescribed Mounjaro for diabetes often see significant weight loss as well, which is why the molecule was also developed and approved as Zepbound for obesity.
Approval and use
| Approved for | Type 2 diabetes |
| Weight use | Weight loss with Mounjaro is off-label; the same molecule is approved for weight management under the brand Zepbound. |
Typical titration (informational)
Mounjaro uses the same low-start, step-up pattern as Zepbound, beginning around 2.5 mg weekly and increasing over months.
The maintenance dose is set by the prescriber for glucose control and tolerance.
Informational only.
Expected timeline
Glucose and appetite effects begin early; weight loss accumulates over months. Magnitude is similar to tirzepatide in obesity trials at comparable doses.
Common side effects
- Nausea and reduced appetite
- Diarrhea, constipation, vomiting
- Hypoglycemia risk when combined with certain diabetes drugs
- Fatigue early on
What happens when you stop Mounjaro
Stopping tirzepatide returns appetite signaling toward baseline while metabolic adaptation persists, so weight tends to climb back without a maintenance system, just like the other GLP-1-class drugs.
For people with diabetes, glucose control may also shift, which is another reason any change is a clinician decision.
Cost
Cash price is in the same range as other branded GLP-1s; diabetes coverage is often broader than weight-management coverage. Verify current pricing.
Frequently asked questions
Can Mounjaro be used for weight loss?
Mounjaro is approved for type 2 diabetes; weight loss is off-label. The same molecule (tirzepatide) is approved for weight management as Zepbound.
Sources & further reading
Every claim on this page is drawn from peer-reviewed research, clinical trials, or recognized health authorities. Read the source before making any decision about your health.